Trials / Completed
CompletedNCT01960790
Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation)
Humira® 40mg Syringe 0.8mL Subcutaneous Injection Special Investigation in Patients With Intestinal Behcet's Disease
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 473 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This investigation was conducted to obtain the following information regarding the use of Adalimumab (Humira®) 40mg Syringe 0.8mL for Subcutaneous Injection in patients with Intestinal Behcet's Disease. 1. Incidence and conditions of occurrence of adverse reactions in clinical practice 2. Factors likely to affect the safety and effectiveness
Conditions
Timeline
- Start date
- 2013-05-25
- Primary completion
- 2017-05-15
- Completion
- 2017-05-15
- First posted
- 2013-10-11
- Last updated
- 2019-03-22
- Results posted
- 2019-03-22
Source: ClinicalTrials.gov record NCT01960790. Inclusion in this directory is not an endorsement.